Genetic and Biological Markers in MPNs

Genetic and biological markers in MPNs: How have they influenced clinical practice?

Professors Constantinescu and Skoda started a discussion on the impact of genetic mutations in myeloproliferative neoplasms (MPNs), looking in particular at diagnosis and prognosis. The discoveries of key driver and somatic mutations in the disease area over the past few years has revolutionised the perception on pathogenesis and disease progression. Both speakers highlighted key milestones in the discovery of mutations, with JAK2 V617F being a key player in risk of thrombosis and more recently the CALR mutation and its role in MPNs. For more insight from the speakers, click on the videos below.

Please click here to download the abstract of the discussion.

Please click here to download Prof. Skoda’s presentation.

Please click here to download Prof. Constantinescu’s presentation.